Computer-aided drug design of β-secretase, γ- secretase and anti-tau inhibitors for the discovery of novel alzheimer’s therapeutics

Varnavas D. Mouchlis, Georgia Melagraki, Lefteris C. Zacharia, Antreas Afantitis

Research output: Contribution to journalReview article

Abstract

Aging-associated neurodegenerative diseases, which are characterized by progressive neuronal death and synapses loss in human brain, are rapidly growing affecting millions of people globally. Alzheimer’s is the most common neurodegenerative disease and it can be caused by genetic and environmental risk factors. This review describes the amyloid-β and Tau hypotheses leading to amyloid plaques and neurofibrillary tangles, respectively which are the predominant pathways for the development of anti-Alzheimer’s small molecule inhibitors. The function and structure of the druggable targets of these two pathways including β-secretase, γ-secretase, and Tau are discussed in this review article. Computer-Aided Drug Design including computational structure-based design and ligand-based design have been employed successfully to develop inhibitors for biomolecular targets involved in Alzheimer’s. The application of computational molecular modeling for the discovery of small molecule inhibitors and modulators for β-secretase and γ-secretase is summarized. Examples of computational approaches employed for the development of anti-amyloid aggregation and anti-Tau phosphorylation, proteolysis and aggregation inhibitors are also reported.

Original languageEnglish
Article number703
JournalInternational Journal of Molecular Sciences
Volume21
Issue number3
DOIs
Publication statusPublished - 1 Feb 2020

Fingerprint

Computer-Aided Design
Amyloid Precursor Protein Secretases
Drug Design
inhibitors
Neurodegenerative diseases
drugs
Amyloid
Agglomeration
Neurodegenerative Diseases
Pharmaceutical Preparations
Proteolysis
Phosphorylation
Molecules
Molecular modeling
synapses
phosphorylation
Modulators
Neurofibrillary Tangles
Brain
Amyloid Plaques

Keywords

  • Alzheimer’s disease
  • Cheminformatics
  • Computational ligand-based design
  • Computational structure-based design
  • Computer-aided drug design
  • Molecular docking
  • Molecular dynamics
  • QSAR
  • Tau
  • β-secretase
  • γ-secretase

Cite this

@article{ff94a7252749481d91947f082afce073,
title = "Computer-aided drug design of β-secretase, γ- secretase and anti-tau inhibitors for the discovery of novel alzheimer’s therapeutics",
abstract = "Aging-associated neurodegenerative diseases, which are characterized by progressive neuronal death and synapses loss in human brain, are rapidly growing affecting millions of people globally. Alzheimer’s is the most common neurodegenerative disease and it can be caused by genetic and environmental risk factors. This review describes the amyloid-β and Tau hypotheses leading to amyloid plaques and neurofibrillary tangles, respectively which are the predominant pathways for the development of anti-Alzheimer’s small molecule inhibitors. The function and structure of the druggable targets of these two pathways including β-secretase, γ-secretase, and Tau are discussed in this review article. Computer-Aided Drug Design including computational structure-based design and ligand-based design have been employed successfully to develop inhibitors for biomolecular targets involved in Alzheimer’s. The application of computational molecular modeling for the discovery of small molecule inhibitors and modulators for β-secretase and γ-secretase is summarized. Examples of computational approaches employed for the development of anti-amyloid aggregation and anti-Tau phosphorylation, proteolysis and aggregation inhibitors are also reported.",
keywords = "Alzheimer’s disease, Cheminformatics, Computational ligand-based design, Computational structure-based design, Computer-aided drug design, Molecular docking, Molecular dynamics, QSAR, Tau, β-secretase, γ-secretase",
author = "Mouchlis, {Varnavas D.} and Georgia Melagraki and Zacharia, {Lefteris C.} and Antreas Afantitis",
year = "2020",
month = "2",
day = "1",
doi = "10.3390/ijms21030703",
language = "English",
volume = "21",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
number = "3",

}

Computer-aided drug design of β-secretase, γ- secretase and anti-tau inhibitors for the discovery of novel alzheimer’s therapeutics. / Mouchlis, Varnavas D.; Melagraki, Georgia; Zacharia, Lefteris C.; Afantitis, Antreas.

In: International Journal of Molecular Sciences, Vol. 21, No. 3, 703, 01.02.2020.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Computer-aided drug design of β-secretase, γ- secretase and anti-tau inhibitors for the discovery of novel alzheimer’s therapeutics

AU - Mouchlis, Varnavas D.

AU - Melagraki, Georgia

AU - Zacharia, Lefteris C.

AU - Afantitis, Antreas

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Aging-associated neurodegenerative diseases, which are characterized by progressive neuronal death and synapses loss in human brain, are rapidly growing affecting millions of people globally. Alzheimer’s is the most common neurodegenerative disease and it can be caused by genetic and environmental risk factors. This review describes the amyloid-β and Tau hypotheses leading to amyloid plaques and neurofibrillary tangles, respectively which are the predominant pathways for the development of anti-Alzheimer’s small molecule inhibitors. The function and structure of the druggable targets of these two pathways including β-secretase, γ-secretase, and Tau are discussed in this review article. Computer-Aided Drug Design including computational structure-based design and ligand-based design have been employed successfully to develop inhibitors for biomolecular targets involved in Alzheimer’s. The application of computational molecular modeling for the discovery of small molecule inhibitors and modulators for β-secretase and γ-secretase is summarized. Examples of computational approaches employed for the development of anti-amyloid aggregation and anti-Tau phosphorylation, proteolysis and aggregation inhibitors are also reported.

AB - Aging-associated neurodegenerative diseases, which are characterized by progressive neuronal death and synapses loss in human brain, are rapidly growing affecting millions of people globally. Alzheimer’s is the most common neurodegenerative disease and it can be caused by genetic and environmental risk factors. This review describes the amyloid-β and Tau hypotheses leading to amyloid plaques and neurofibrillary tangles, respectively which are the predominant pathways for the development of anti-Alzheimer’s small molecule inhibitors. The function and structure of the druggable targets of these two pathways including β-secretase, γ-secretase, and Tau are discussed in this review article. Computer-Aided Drug Design including computational structure-based design and ligand-based design have been employed successfully to develop inhibitors for biomolecular targets involved in Alzheimer’s. The application of computational molecular modeling for the discovery of small molecule inhibitors and modulators for β-secretase and γ-secretase is summarized. Examples of computational approaches employed for the development of anti-amyloid aggregation and anti-Tau phosphorylation, proteolysis and aggregation inhibitors are also reported.

KW - Alzheimer’s disease

KW - Cheminformatics

KW - Computational ligand-based design

KW - Computational structure-based design

KW - Computer-aided drug design

KW - Molecular docking

KW - Molecular dynamics

KW - QSAR

KW - Tau

KW - β-secretase

KW - γ-secretase

UR - http://www.scopus.com/inward/record.url?scp=85078271173&partnerID=8YFLogxK

U2 - 10.3390/ijms21030703

DO - 10.3390/ijms21030703

M3 - Review article

C2 - 31973122

AN - SCOPUS:85078271173

VL - 21

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 3

M1 - 703

ER -